Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1963 1
1967 1
1968 2
1969 4
1971 6
1972 8
1973 5
1974 7
1975 10
1976 7
1977 13
1978 12
1979 9
1980 8
1981 12
1982 12
1983 11
1984 8
1985 10
1986 25
1987 15
1988 17
1989 12
1990 12
1991 13
1992 19
1993 10
1994 15
1995 9
1996 10
1997 8
1998 7
1999 5
2000 6
2001 15
2002 6
2003 9
2004 12
2005 11
2006 11
2007 6
2008 5
2009 5
2010 5
2011 7
2012 5
2013 2
2015 1
2016 2
2017 3
2018 2
2019 3
2020 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

433 results
Results by year
Filters applied: . Clear all
Page 1
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Perkovic V, et al. Among authors: brenner bm. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14. N Engl J Med. 2019. PMID: 30990260 Free article. Clinical Trial.
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V. Mahaffey KW, et al. Among authors: brenner bm. Circulation. 2019 Aug 27;140(9):739-750. doi: 10.1161/CIRCULATIONAHA.119.042007. Epub 2019 Jul 11. Circulation. 2019. PMID: 31291786 Free PMC article. Clinical Trial.
Defining renal risk.
Taal MW, Brenner BM. Taal MW, et al. Among authors: brenner bm. Curr Opin Nephrol Hypertens. 2007 Nov;16(6):554-6. doi: 10.1097/MNH.0b013e3282f09f26. Curr Opin Nephrol Hypertens. 2007. PMID: 18089970 Review. No abstract available.
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators. Jardine MJ, et al. Among authors: brenner bm. Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633. Online ahead of print. Am J Nephrol. 2017. PMID: 29253846 Free PMC article.
The clinical importance of nephron mass.
Luyckx VA, Brenner BM. Luyckx VA, et al. Among authors: brenner bm. J Am Soc Nephrol. 2010 Jun;21(6):898-910. doi: 10.1681/ASN.2009121248. Epub 2010 Feb 11. J Am Soc Nephrol. 2010. PMID: 20150537 Free article. Review.
Biologically active atrial peptides.
Ballerman BJ, Brenner BM. Ballerman BJ, et al. Among authors: brenner bm. J Clin Invest. 1985 Dec;76(6):2041-8. doi: 10.1172/JCI112206. J Clin Invest. 1985. PMID: 3001138 Free PMC article. Review. No abstract available.
433 results